Cyclofluidic announces first fully automated lead discovery experiment

Cyclofluidic has announced the completion of the first fully automated “screen and test” lead discovery experiment. Scientists used the company’s proprietary microfluidic system to design, make and screen potential drug molecules active against thrombin, a target associated with stroke.

The Cyclofluidic Integrated Discovery Platform uses microfluidic flow chemistry, on-line biochemical assays and automated drug design algorithms to make and screen potential drug molecules. “This is a key milestone for Cyclofluidic” said Chris Selway, Cyclofluidic’s Chief Technology Officer, “the majority of the drug molecules in this experiment were designed, made and tested by the platform overnight.”

*******

Contact:  Elizabeth Farrant

00 44 (0)1707 358706

00 44 (0)7930 853662

elizabeth.farrant@cyclofluidic.co.uk

________________________________________





Read more

Looking for something specific?